Karyopharm Therapeutics (KPTI) Change in Receivables (2019 - 2025)

Karyopharm Therapeutics has reported Change in Receivables for 7 years, with the latest figure at -$5.7 million in Q4 2025.

• For the quarter ending Q4 2025, Change in Receivables fell 463.14% year-over-year to -$5.7 million; the trailing twelve-month figure through Dec 2025 stood at -$4.6 million (down 220.61% YoY), and the FY2025 full-year result was -$4.6 million, down 220.61% from the prior year.
• Change in Receivables for Q4 2025 stood at -$5.7 million, down from -$1.1 million in the prior quarter.
• The five-year high for Change in Receivables was $6.9 million in Q2 2024, with the low at -$11.9 million in Q1 2023.
• Historically, Change in Receivables has averaged -$310400.0 across 5 years, with a median of $89500.0 in 2021.
• Annual changes were most pronounced in 2022 — Change in Receivables surged 358.61% — and 2023, when it plunged 8219.26%.
• Karyopharm Therapeutics' Change in Receivables stood at $3.7 million in 2021, then plunged by 96.4% to $135000.0 in 2022, then sank by 8219.26% to -$11.0 million in 2023, then jumped by 90.77% to -$1.0 million in 2024, then slumped by 463.14% to -$5.7 million in 2025.
• The last three Change in Receivables figures came in at -$5.7 million (Q4 2025), -$1.1 million (Q3 2025), and -$2.3 million (Q2 2025), per Business Quant data.